In myelodysplastic syndromes (MDS) and AML, TET2 mutations are present in 20%–30% of cases, ranging up to 50% in patients affected by chronic myelomonocytic leukemia (CMML) [27,28,29]. The gene discussed is TET2; the disease is chronic myelomonocytic leukemia.